CytoReason Introduces AI Chat Assistant for Pharmaceutical Research at JPM HealthCare Conference 2026

NVIDIA-Backed Tool Uses Molecular Data to Support Drug Development Analysis

CytoReason launched an artificial intelligence chat-style assistant for pharmaceutical research and development during the JPM HealthCare Conference 2026. The assistant, called LINA, is designed to support drug development activities using molecular and biological data.

According to the company, LINA is built on CytoReason’s artificial intelligence framework and is trained on a large set of drug development questions used across the pharmaceutical industry. The system allows researchers to query disease biology through a conversational interface and review outputs generated from underlying molecular data.

The assistant is powered by NVIDIA accelerated computing. NVIDIA is a strategic investor in CytoReason, and the companies reported that the technology will be deployed by pharmaceutical customers, including Takeda.

CytoReason stated that LINA supports research workflows by generating summaries, visualizations, and reports related to disease mechanisms and drug development questions. The tool is intended for use across multiple stages of pharmaceutical research and development.